Expert opinions of the first Italian Consensus Conference on the management of malignant pleural mesothelioma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 1, 2011, Pages 99-109

  Pinto, Carmine ^a   Ardizzoni, Andrea ^b   Betta, Pier Giacomo ^c   Facciolo, Francesco ^d   Tassi, Gianfranco ^e   Tonoli, Sandro ^f   Zompatori, Maurizio ^a   Alessandrini, Gabriele ^d   Magrini, Stefano Maria ^f   Tiseo, Marcello ^b   Mutri, Vita ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c C Arrigo Children's Hospital   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^e Civil Hospital   (Italy)

^f UNIVERSITY OF BRESCIA   (Italy)

Author keywords

malignant pleural mesothelioma

Indexed keywords

CARBOPLATIN; CISPLATIN; CONTRAST MEDIUM; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; METHOTREXATE; MITOMYCIN; NAVELBINE; OSTEOPONTIN; PEMETREXED; PLATINUM; PLATINUM COMPLEX; RALTITREXED; RANPIRNASE; SOLUBLE MESOTHELIN RELATED PROTEIN; TALC; TAXANE DERIVATIVE; TUMOR MARKER; UNCLASSIFIED DRUG; VINBLASTINE; VINFLUNINE;

ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CANCER GENETICS; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHRONOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; CONTRAST ENHANCEMENT; CYTOGENETICS; DIAGNOSTIC ACCURACY; DISTANT METASTASIS; DRUG EFFICACY; ECHOGRAPHY; EXPERT SYSTEM; EXTRAPLEURAL PNEUMONECTOMY; FALSE POSITIVE RESULT; FOLLOW UP; GERIATRIC CARE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTENSITY MODULATED RADIATION THERAPY; ITALY; LAPAROSCOPY; LUNG DISEASE; LUNG FUNCTION TEST; LUNG RESECTION; LUNG SCINTISCANNING; LYMPH NODE METASTASIS; MALIGNANT MESOTHELIOMA; MEDIASTINOSCOPY; MICROSCOPY; MOLECULAR BIOLOGY; MONOTHERAPY; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA BIOPSY; PLEURA EFFUSION; PLEURA FLUID; PLEURA MESOTHELIOMA; PLEURA POUDRAGE; PLEURECTOMY; PLEURODESIS; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; QUALITY OF LIFE; RADIATION DOSE; RADIATION INDUCED EMESIS; RADIATION INJURY; RADIATION SICKNESS; RADIODIAGNOSIS; RECURRENT DISEASE; SENSITIVITY AND SPECIFICITY; THERAPY DELAY; THORACOCENTESIS; THORACOSCOPY; THORAX DRAINAGE; THORAX RADIOGRAPHY; TRAPPED LUNG SYNDROME; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; ITALY; LAPAROSCOPY; MALE; MESOTHELIOMA; PLEURAL NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RADIOTHERAPY, ADJUVANT; RESPIRATORY FUNCTION TESTS; THORACIC SURGICAL PROCEDURES; THORACOSCOPY;

EID: 79951673779     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181d31f02     Document Type: Article

References (88)

1. ISPeSL. Registro Nazionale dei Mesoteliomi, Secondo Rapporto. Rome, Italy: ISPeSL; 2006.
2. Marinaccio A, Nesti M. Analysis of survival of mesothelioma cases in the Italian register. Eur J Cancer. 2003;39:1290-1295. (Pubitemid 36579202)
3. Montanaro F, Rosato R, Gangemi M, et al. Survival of pleural malignant mesothelioma in Italy: a population-based study. Int J Cancer. 2009;124: 201-207.
4. Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic. Br J Cancer. 1999;79:666-672. (Pubitemid 29046253)
5. Addis B, Roche H. Problems in mesothelioma diagnosis. Histopathology. 2009;54:55-68.
6. Amie AY, Raz DJ, He B, et al. Update on the molecular biology of malignant mesothelioma. Cancer. 2007;109:1454-1461. (Pubitemid 46595678)
7. Amin W, Parwani AV, Schmandt L, et al. National mesothelioma virtual bank: a standard based biospecimen and clinical data resource to enhance translational research. BMC Cancer. 2008;8:236.
8. Attanoos RL, Gibbs AR. The comparative accuracy of different pleural biopsy techniques in the diagnosis of malignant mesothelioma. Histopathol-ogy. 2008;53:340-344.
9. Cagle PT, Churg A. Differential diagnosis of benign and malignant mesothe-lial proliferations on pleural biopsies. Arch Pathol Lab Med. 2005;129:1421-1427. (Pubitemid 41587017)
10. Greillier L, Baas P, Welch JJ, et al. Biomarkers for malignant pleural mesothelioma: current status. Mol Diagn Ther. 2008;12:375-390. (Pubitemid 352790451)
11. Grigoriu BD, Grégoire M, Chahine B, et al. New diagnostic markers for malignant pleural mesothelioma. Bull Cancer. 2008;95:177-184. (Pubitemid 351341288)
12. Marchevsky AM. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med. 2008;132:397-401. (Pubitemid 351328814)
13. Pereira T, Saad RS, Liu Y, et al. The diagnosis of malignancy in effusion cytology: a pattern recognition approach. Adv Anat Pathol. 2006;13:174-184. (Pubitemid 44341653)
14. Suster S, Moran CA. Applications and limitations of immunohistochemistry in the diagnosis of malignant mesothelioma. Adv Anat Pathol. 2006;13:316-329. (Pubitemid 44673447)
15. Alvarez JM, Ha T, Musk W, et al. Importance of mediastinoscopy, bilateral thoracoscopy, and laparoscopy in correct staging of malignant mesothelioma before extrapleural pneumonectomy. J Thorac Cardiovasc Surg. 2005;130: 905-906. (Pubitemid 41265749)
16. Scherpereel A, French Speaking Society for Chest Medicine (SPLF) Experts Group. Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma. Respir Med. 2007;101: 1265-1276.
17. Beckles MA, Spri SG, Colice GL, et al. The physiologic evaluation of patients with lung cancer being considered for resectional surgery. Chest. 2003;123:105-114.
18. Blanc FX, Atassi K, Bignon J, et al. Diagnostic value of medical thoracoscopy in pleural disease: a 6-year retrospective study. Chest. 2002;121:1677-1683. (Pubitemid 34499687)
19. Bonnette P. Radical surgery for mesothelioma. Cancer Radiother. 2007;11: 101-104.
20. Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: diagnosis. Cancer. 1993; 72:389-393. (Pubitemid 23193443)
21. Boutin C, Schlesser M, Frenay C, et al. Malignant pleural mesothelioma. Eur Respir J. 1998;12:972-981. (Pubitemid 28491677)
22. British Thoracic Society; Society of Cardiothoracic Surgeons of Great Britain and Ireland Working Party. BTS guidelines: guidelines on the selection of patients with lung cancer for surgery. Thorax. 2001;56:89-108.
23. British Thoracic Society Standard of Care Committee. BTS statement on malignant mesothelioma in the UK 2007. Thorax. 2007; 62: 1-19.
24. Colice GL, Shafazand S, Griffin JP, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007;132: 161-177.
25. Conlon KC, Rusch VW, Gillern S. Laparoscopy: an important tool in the staging of malignant pleural mesothelioma. Ann Surg Oncol. 1996;3:489-494. (Pubitemid 126728595)
26. Koegelenberg CF, Bolliger CT. Assessing regional lung function. Thorac Surg Clin. 2008;18:19-29. (Pubitemid 351180014)
27. Rice DC, Erasmus JJ, Stevens CW, et al. Extended surgical staging for potentially resectable malignantpleural mesothelioma. Ann Thorac Surg. 2005;80:1988-1992.
28. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest group. Chest. 1995;108:1122-1128.
29. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy for malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54-63.
30. Abdel Rahman AR, Gaafar RM, Baki HA, et al. Prevalence and pattern of lymph node metastasis in malignant pleural mesothelioma. Ann Thorac Surg. 2008;86:391-395. (Pubitemid 351978029)
31. American Joint Committee on Cancer, Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Handbook. 6th ed. New York, NY: Springer-Verlag; 2002.
32. Aziz T, Jilaihawi A, Prakash D. The management of malignant pleural mesothelioma; single centre experience in 10 years. Eur J Cardiothorac Surg. 2002;22:298-305. (Pubitemid 34831874)
33. Edwards JG, Stewart DJ, Martin-Ucar AE, et al. The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma. J Thorac Cardiovasc Surg. 2006;131:981-987.
34. Flores RM, Akhurst T, Gonen M, et al. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2003;126:11-16. (Pubitemid 36909936)
35. Flores RM, Krug LM, Rosenzweig KE, et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol. 2006;1:289-295. (Pubitemid 47163979)
36. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135: 620-626.
37. Flores RM, Zakowsky M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol. 2007;2:957-965. (Pubitemid 47511601)
38. Grunenwald D. [Malignant pleural mesothelioma. Role of surgery]. Rev Pneumol Clin. 200;61:8-9.
39. Gupta V, Mychalczak B, Krug L, et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2005;63:1045-1052. (Pubitemid 41505282)
40. Janne PA, Baldini EH. Patterns of failure following surgical resection for malignant pleural mesothelioma. Thorac Surg Clin. 2004;14:567-573. (Pubitemid 39314491)
41. Kolschmann S, Ballin A, Gillissen A. Clinical efficacy and safety of thora-coscopic talc pleurodesis in malignant pleural effusions. Chest. 2005;128: 1431-1435. (Pubitemid 41324428)
42. Mahe MA, Cellerin L, Michaud JL, et al. Recent progress in treatment of malignant pleural mesothelioma. Cancer Radiother. 2005;9:362-365. (Pubitemid 41719042)
43. Martin-Ucar AE, Nakas A, Edwards JG, et al. Case-control study between extrapleural pneumonectomy and radical pleurectomy/decortication for pathological N2 malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2007;31:765-771.
44. Neragi-Miandoab S. Multimodality approach in management of malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2006;29:14-19. (Pubitemid 43000349)
45. Pilling JE, Stewart DJ, Martin-Ucar AE, et al. The case for routine cervical mediastinoscopy prior to radical surgery for malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2004;25:497-501. (Pubitemid 38376059)
46. Rice DC, Erasmus JJ, Stevens CW, et al. Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg. 2005;80:1988-1992.
47. Rice D. Surgery for malignant pleural mesothelioma. Ann Diagn Pathol. 2009;13:65-72.
48. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonec-tomy in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 1991; 102:1-9.
49. Rusch VW. Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma. Sem Thorac Cardiovasc Surg. 1997;9:367-372.
50. Rusch VW, Venkatraman E. The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 1996;111:815-825.
51. Schouwink JH, Kool LS, Rutgers EJ, et al. The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma. Ann Thorac Surg. 2003;75: 1715-1718. (Pubitemid 36677200)
52. Stewart DJ, Martin-Ucar A, Pilling JE, et al. The effect of extent of local resection on patterns of disease progression in malignant pleural mesotheli-oma. Ann Thorac Surg. 2004;78:245-252. (Pubitemid 38833940)
53. Sugarbaker DJ. Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma. J Thorac Oncol. 2006;1: 175-176. (Pubitemid 47164008)
54. Sugarbaker DJ, Strauss GM, Lynch TJ, et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol. 1993;11:1172-1178. (Pubitemid 23163360)
55. Yajnik S, Rosenzweig KE, Mychalczak B, et al. Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int J Ra-diat Oncol Biol Phys. 2003;56:1319-1326. (Pubitemid 36842883)
56. Ceresoli GL, Castagneto B, Zucali PA, et al. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. Br J Cancer. 2008;99:51-56. (Pubitemid 351920240)
57. Ellis P, Davies AM, Evans WK, et al. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guidelines. J Thorac Oncol. 2006;1:591-601. (Pubitemid 47181411)
58. Fennell DA, Gaudino G, O'Byrne KJ, et al. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol. 2008;5:136-147.
59. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135: 620-626.
60. Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008; 26:1698-1704.
61. Krug LM, Pass HI, Rusch VW, et al. A multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonec-tomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27:3007-3013.
62. Manegold C, Symanowski J, Gatzemeier U, et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005;16:923-927. (Pubitemid 40903918)
63. Muers Mf, Stephens RJ, Fisher P, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicenter randomized trial. Lancet. 2008;371: 1640-1642.
64. O'Brien ME, Watkins D, Ryan C, et al. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symp-tomatically stable patients: the MED trial. Ann Oncol. 2006;17:270-275. (Pubitemid 43160117)
65. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma. A review. J Clin Oncol. 1996;14:1007-1017. (Pubitemid 26085549)
66. Ramalingam SS, Belani C. Recent advances in the treatment of malignant pleural mesothelioma. J Thorac Oncol. 2008;3:1056-1064.
67. Santoro A, O'Brien ME, Stahel RA, et al. Pemetrexed plus cisplatin or pemetrexed plus carbolatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Tho-rac Oncol. 2008;3:756-763.
68. Sugarbaker DJ, Norberto JJ. Multimodality management of malignant pleural mesothelioma. Chest. 1998;113:61-65.
69. Van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23:6881-6889.
70. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636-2644. (Pubitemid 46606305)
71. Weder W, Stahel RA, Bernhard J, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol. 2007;18:1196-1202. (Pubitemid 47244366)
72. Ahamed A, Stevens CW, Smythe WR, et al. Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothe-lioma. Int J Radiat Oncol Biol Phys. 2003;55:768-775. (Pubitemid 36170016)
73. Ahamed A, Stevens CW, Smythe WR, et al. Promising early local control of malignant pleural mesothelioma following postoperative Intensity Modulated Radiotherapy (IMRT) to the chest. Cancer J. 2003;9:476-484. (Pubitemid 44403485)
74. Allen AM, Czerminska M, Janne PA, et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiation Oncology Biol Phys. 2006;65:640-645. (Pubitemid 43795851)
75. Allen AM, Den R, Wong JS, et al. Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy. Int J Radiat Oncol Biol Phys. 2007;68:1366-1374. (Pubitemid 47176807)
76. Baldini EH, Rech A, Strass GM, et al. Patterns of failure after trimodality therapy for malignant mesothelioma. Ann Thorac Surg. 1997;63:334-338. (Pubitemid 27084548)
77. Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest. 1995;108:754-758.
78. Bydder S, Philips M, Joseph DJ, et al. A randomised trial of single dose radiotherapy to prevent procedure tract metastasis by malignant mesotheli-oma. Br J Cancer. 2004;91:9-10. (Pubitemid 39013037)
79. Davis SR, Tan L, Ball DL. Radiotherapy in the treatment of malignant mesothelioma with special reference to its use in palliation. Aust Radiol. 1994;38:212-214. (Pubitemid 24247737)
80. De Graaf-Strukowska L, Van der Zee J, Van Putten W, et al. Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura: a single institution experience with 189 patients. Int J Radiat Oncol Biol Phys. 1999;43:511-516. (Pubitemid 29107168)
81. De Ruysscher D, Slotman B. Treatment of intervention sites of malignant pleural mesothelioma with radiotherapy: a Dutch-Belgian survey. Radiother Oncol. 2003;68:299-302. (Pubitemid 38373432)
82. Frata P, Marchetti GP, Mazzù L., et al. Il ruolo della radioterapia nella prevenzione della ricaduta locale dopo toracoscopia nel mesotelioma maligno della pleura. Rassegna Patologia Apparato Respiratorio. 2003;18:364-367.
83. Jaklitsch MT, Grondi SC, Sugarbaker DJ. Treatment of malignant mesothe-lioma. World J Surg. 2001;25:210-217.
84. O'Rourke N, Garcia GC, Paul J, et al. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol. 2007;84:18-22. (Pubitemid 47030694)
85. Pistolesi M, Rusthove J. Malignant pleural mesothelioma, update, current management, and newer therapeutic strategies. Chest. 2004;126:1318-1329. (Pubitemid 39391267)
86. Rice DC, Smythe WR, Liao Z, et al. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural me-sothelioma. Int J Radiat Oncol Biol Phys. 2007;69:350-357. (Pubitemid 47381562)
87. Rusch VW. Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma. Chest. 1993;103:382-384.
88. Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemothoracic radiation for malignant pleu-ral mesothelioma. J Thorac Cardiovasc Surg. 2001;122:788-795.